| Next 10 |
Ad
MURA News and Press Mural Oncology plc
News | Mural Oncology plc (NASDAQ:MURA)
-
2025-04-15 16:55:00 ET A biotech company based out of Ireland saw its shares soar on Tuesday after the company announced that it is discontinuing all clinical development of nemvaleukin alfa and plans to immediately start exploring strategic alternatives. Traders rushed to buy up sh...
-
2025-04-15 10:34:57 ET DENVER, Colo., Apr 15, 2025 ( 247marketnews.com ) -Today’s top news and trades include weight loss and super fibers. MetaVia (NASDAQ:MTVA) unveiled Phase 1 MAD trial results for DA-1726, its novel 3:1 ratio GLP-1/glucagon dual receptor agonist aimed at ...
-
2025-04-15 08:47:35 ET DENVER, Colo., Apr 15, 2025 ( 247marketnews.com )- Mural Oncology (NASDAQ:MURA) stated that it’s halting all clinical development of nemvaleukin alfa and launching a high-stakes hunt for strategic alternatives to maximize shareholder value, backed by a heft...
-
2025-03-28 11:13:08 ET Summary Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa, which failed to show significant overall survival benefits in PROC. The trial's failure delays any potential NDA submission, impacting the commercia...
-
2025-03-25 08:27:22 ET More on Alkermes, Mural Oncology, etc. Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript Alkermes plc 2024 Q4 - Results - Earnings Call Presentation Al...
-
2025-03-11 18:11:10 ET More on Mural Oncology Seeking Alpha’s Quant Rating on Mural Oncology Historical earnings data for Mural Oncology Financial information for Mural Oncology Read the full article on Seeking Alpha For further details see: ...
-
WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways, today announced that CEO Caroline Loew, Ph.D., will present at the TD Cow...
-
Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutane...
-
2024-11-24 09:58:43 ET Summary Alkermes has shifted from royalty-based revenues to proprietary product sales, driven by strong growth in Lybalvi, Vivitrol, and Aristada. ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy and hypersomnia, represents a transformative oppo...
-
Nemvaleukin was generally well tolerated in ARTISTRY-1, a completed phase 1/2 clinical trial, with durable responses observed in both monotherapy and combination therapy across a range of heavily pretreated advanced solid tumors, including in platinum-resistant ovarian cancer (PROC), which does n...
Stock Information
Get MURA Alerts
News, Short Squeeze, Breakout and More Instantly...
Mural Oncology plc Company Name:
MURA Stock Symbol:
NASDAQ Market:
-0.38% G/L:
$2.60 Last:
434,612 Volume:
$2.65 Open:
$2.60 Close:
Ad
-
2025-04-15 16:55:00 ET A biotech company based out of Ireland saw its shares soar on Tuesday after the company announced that it is discontinuing all clinical development of nemvaleukin alfa and plans to immediately start exploring strategic alternatives. Traders rushed to buy up sh...
-
2025-04-15 10:34:57 ET DENVER, Colo., Apr 15, 2025 ( 247marketnews.com ) -Today’s top news and trades include weight loss and super fibers. MetaVia (NASDAQ:MTVA) unveiled Phase 1 MAD trial results for DA-1726, its novel 3:1 ratio GLP-1/glucagon dual receptor agonist aimed at ...
-
2025-04-15 08:47:35 ET DENVER, Colo., Apr 15, 2025 ( 247marketnews.com )- Mural Oncology (NASDAQ:MURA) stated that it’s halting all clinical development of nemvaleukin alfa and launching a high-stakes hunt for strategic alternatives to maximize shareholder value, backed by a heft...